08:30-08:35

08:35-08:55

 

08:55-09:15

  

09:15-09:35

  

09:35-09:55

 

Islet fat

E. Ravussin, USA  

Intramyocellular

R.A. DeFronzo, USA   

Visceral fat/Nonalcoholic Steatohepatitis (NASH)

G. Perseghin, Italy        

Myocardial/perivascular/epicardical fat

            

10:30-10:35

10:35-11:05

  

11:05-11:35

  

11:35-12:05

 

12:05-12:30

Hypoglycemia and CV risks

ACCORD, ADVANCE and VADT

Hypoglycaemia and its potential contribution to fatal cardiac arrhythmias in T1D and T2D

PANEL DISCUSSION

               

Poster Presentation Area

 

 

 

IDENTIFICATION OF NEW TARGET FOR OBESITY AND TYPE II DIABETES TREATMENT BASED ON GENES ASSOCIATED WITH LEAN PHENOTYPE IN HUMAN AND VALIDATION OF THE TARGET BY GENE INACTIVATION IN MICE
I. Harosh, France

 
VEGETARIAN DIET IMPROVES INSULIN RESISTANCE AND OXIDATIVE STRESS MARKERS IN SUBJECTS WITH T2DM
H. Kahleova, Czech Republic, M. Matoulek, H. Malinska, O. Oliyarnik, L. Kazdova, T. Neskudla, A. Skoch, M. Hajek, M. Hill, T. Pelikanova

 
WEIGHT LOSS WITH CONTROLLED-RELEASE PHEN/TPM DRIVES IMPROVEMENT IN COMORBIDITIES IN OVERWEIGHT AND OBESE SUBJECTS
W.T. Garvey, USA, K. Gadde, C. Peterson, W.W. Day

 
HUMAN OBESITY IS CHARACTERIZED BY DEFECTIVE FAT STORAGE AND ENHANCED SKELETAL MUSCLE FA OXIDATION
M. Bucci, Finland, R. Borra, K. Någren, S. Del Ry, R. Maggio, H. Tuunanen, M. Taittonen, D. Giannessi, R. Parkkola, J. Knuuti, P.Nuutila, P.Iozzo

 

14:15-14:20

14:20-14:45

 

14:45-15:10

 

15:10-15:35

 

15:35-16:00

 

Incretins

Sulfonylurea

PPAR-agonists: Safety issues

PANEL DISCUSSION    

  

16:30-16:35

16:35-16:50

16:50-17:05

17:05-17:20

  

17:20-18:00

17:20-17:40

17:40-18:00

18:00-18:30

Is hyperglycemia a CV risk factor?
Pro: M. Hanefeld, Germany

AUDIENCE DISCUSSION  

 

The heart in diabetes
A macrovascular disease: D. Tschöpe, Germany

A microvascular disease: M. Laakso, Finland

PANEL DISCUSSION

           

08:30-08:35

08:35-08:55

 

08:55-09:15

 

09:15-09:35

 

09:35-10:00

Renally impaired T2DM

T2DM with vascular complications. What is the target? Which treatment?

P. Pozzilli, Italy  

Multidrug treatment of T2DM, a challenge for compliance

PANEL DISCUSSION 

     

10:30-10:35

10:35-10:50

10:50-11:05

11:05-11:20

  

11:20-11:40

11:40-12:00

12:00-12:30

Insulin therapy in T2D
Not too soon: H. Lebovitz, USA

 

HbA1c targets should be individualized for all patients with DM

Pro: P. Home, UK  

Con: L. Leiter, Canada    

PANEL DISCUSSION 

               

Poster Presentation Area

 

 

 

THE ALAURSO STUDY
G. Troisi, V. Gianturco, Italy, A. Bellomo, M. Cirene, E.  D'Ottavio, V.  Formosa, R.  Frezza, A. Lori, B.  Marigliano, V. Marigliano

 
EFFECTS OF TESTOSTERONE METABOLIC SYNDROME AND INFLAMMATION IN HYPOGONADAL MEN: THE MOSCOW STUDY
A. Saad, Germany, Y. Kalinchenko, A. Tishova, J. Mskhalaya, J.G. Gooren, J. Giltay

 

CHRONIC PERIODONTITIS AS A RISK FACTOR FOR DYSLIPIDAEMIC ATHEROGENESIS AND DIABETES: A BIDIRECTIONAL RELATIONSHIP?
M. Soory, UK

 
THE EFFICACY OF LIRAGLUTIDE IS NOT IMPACTED IN SUBJECTS POSITIVE FOR ANTI-LIRAGLUTIDE ANTIBODIES: A POOLED ANALYSIS
A.J. Garber, USA, M. Marre, M.A. Nauck, D. Russell-Jones, J. Brett, M. During, L. Blonde

 

 

14:15-14:20

14:20-14:40

 

14:40-15:00

 

 

15:00-15:15

15:15-15:30

15:30-16:00

 

Novel mechanisms for the treatment of T2DM

The role of bile acid in T2D treatment

Y. Handlesman, USA 

 

Anti-platelet therapy for every diabetic person?
Pro: E. Standl, Germany

Con: A. Nicolucci,  Italy     

PANEL DISCUSSION 

 

16:30-16:35

16:35-17:00

 

17:00-17:30

 

17:30-17:55

 

17:55-18:30

Can we manipulate fat tissue to improve the metabolic syndrome without weight loss

N. Stern, Israel      
Comparative efficiency and safety

Sibutramine on CV outcome

PANEL DISCUSSION 

V. Hainer, Czech Republic  A. Scheen, Belgium N. Stern, Israel      

        

08:30-08:35

08:35-08:55

 

08:55-09:15

 

09:15-09:35

 

09:35-09:55

 

The evidence

G. Schernthaner, Austria        
The mechanism

The risk

A. Keidar, Israel         
PANEL DISCUSSION

 

10:30-10:35

10:35-10:55

10:55-11:15

11:15-11:35

 

11:35-12:00

 

12:00-12:30

 

Risk assessment of universal treatment
J. Meigs, USA

PANEL DISCUSSION 

      

Poster Presentation Area

 

 

 

 

INCREASED PULSE PRESSURE AND “SBP x HR” PRODUCT, AND CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS
J. Scheen, Belgium, M. Marchand, J.C. Philips

 

CARDIAC AUTONOMIC DYSFUNCTION IS RELATED TO SLEEP-DISORDERED BREATHING IN NONOBESE DIABETIC SUBJECT
H. Koshiyama, Japan, K. Nomura, H. Ikeda, S. Honjo, Y. Kawasaki, Y. Wada, Y. Hamamoto

  

EFFECTS OF PHYSIOLOGICAL HYPERINSULINAEMIA ON THE  MICROCIRCULATION
A. Jonk, The Netherlands, J.H.M. Houben, L.H. Link, N.C. Schaper, P.W. de Leeuw, E.H. Serné, Y.M. Smulders, C.D.A.Stehouwer

 

HYPERTRIGLYCERIDEMIC WAIST PHENOTYPE IS ASSOCIATED WITH INCREASES IN SMALL DENSE LDL BUT NOT IN TOTAL LDL CHOLESTEROL LEVELS
K.S. Lalic, Serbia, M. Zamaklar, M. Lalic, V. Kalimanovska, A. Jotic, N. Rajkovic  L. Lukic, T. Milicic, S. Singh, L. Stosic
   

 

14:15-14:20

14:20-14:40

  

14:40-15:00

 

15:00-15:20

  

15:20-15:40

 

15:40-16:00

Evolutionary perspectives on addiction leading to smoking, obesity and drug abuse

P.M. Nilsson, Sweden       
Nicotine dependence. Why, how and when?

K.O. Fagerström, Sweden  

Smoking. The global epidemic

R. Fagard, Belgium 

Smoking cessation strategies. The evidence. Non-pharmacological support and counseling

P. Tønnesen, Denmark

PANEL DISCUSSION
R. Fagard, Belgium K.O. Fagerström, Sweden P.M. Nilsson, Sweden P. Tønnesen, Denmark 

 

16:30-18:30
16:30-16:35

Chairperson: J.P. Després, Canada 

16:35-16:55

 

16:55-17:15

 

17:15-17:35

 

17:35-17:55

 

17:55-18:30

Obesity management: Beyond weight loss

Reducing visceral adiposity/ ectopic fat: A better therapeutic target than weight loss?

Variation in body weight associated with hypoglycaemic medication: More than a side effect in T2D

M. Theodorakis, Greece

Novel hypoglycemic agents inducing weight loss

PANEL DISCUSSION